EASTERN COOPERATIVE ONCOLOGY GROUP

描述(申请人提供)：阿尔伯特·爱因斯坦医学院癌症中心(AECC)是NCI指定的癌症中心，自1971年以来一直得到持续资助。我们的具体目标是通过进行创新的临床试验，在可行的情况下进行具有广泛应用潜力的翻译成分的临床试验，以改善癌症的治疗和我们对其生物学的理解。患者从四家附属医院招募，每年约有4000名新癌症患者，25名全职教职员工和20名血液学/肿瘤学研究员，由18名研究人员提供支持。在上一个赠款周期，AECC成员撰写或共同撰写了41篇手稿和25篇与ECOG研究相关的摘要，招募了332名患者参加ECOG/CTSU试验，主持或联合主持了23项研究(包括两项试验[E1199，E2197]，共收集了8000多名患者)，启动或报告了四项新的ECOG试验，这些试验部分或全部基于AECC初步研究(E1199、E3198、E3493、E1494)，并在乳房(J.Sparano)、胃肠道(L.Augenlicht)、白血病(R.Gallagher)、淋巴瘤(J.Sparano)和胸部委员会(S.Keller、R.Perez-Soler)提供科学领导。AECC的研究人员还获得了资金，以支持与ECOG研究相关的白血病、妇科癌症和胃肠道癌症的翻译研究。其他积极的临床研究计划包括一项实验疗法计划，该计划每年在第一阶段研究中招募约100名患者，并参与第二阶段CTEP联合体，提供一个促进药物开发的环境，可以被带到ECOG；这方面的例子包括几项ECOG研究，其中包括在AECC进行的I-II阶段开发的BMS-247550(E2103、E3800、E2301)。AECC为130万人提供种族和经济多样化的服务，其中70%的居民是少数族裔，31%的居民生活在贫困线以下，这一点在ECOG/CTSU试验中反映了近70%的少数族裔招募。在附属市立医院建立临床研究计划和社区肿瘤学计划将有助于进一步提高少数族裔的收益。2001年7月招聘了一位国际知名的内科科学家(R.Perez-Soler)担任内科肿瘤学系主任和癌症中心副主任，同时还招聘了17名新教员，这将有助于进一步加强调查人员的积极核心，并加强该小组对经社理事会的贡献。

DESCRIPTION (provided by applicant): The Albert Einstein College of Medicine Cancer Center (AECC) is an NCI-designated Cancer Center that has been continuously funded since 1971. Our specific aims are to improve the treatment of cancer and our understanding of its biology by conducting innovative clinical trials with translational components when feasible that offer the potential for broad application. Patients are recruited from four affiliated hospitals that see approximately 4000 new cancer patients each year, with 25 full time faculty members and 20 hematology/oncology fellows supported by 18 research staff. During the last grant cycle, AECC members authored or co-authored 41 manuscripts and 25 abstracts related to ECOG studies, enrolled 332 patients on ECOG/CTSU trials, chaired or co-chaired 23 studies (including two trials [E1199, E2197] that accrued over 8000 patients), initiated or reported four new ECOG trials that were based partly or wholly on AECC pilot studies (E1199, E3198, E3493, E1494), and provided scientific leadership in the breast (J. Sparano), gastrointestinal (L. Augenlicht), leukemia (R. Gallagher), lymphoma (J. Sparano), and thoracic committees (S. Keller, R. Perez-Soler). AECC investigators also secured funding to support translational studies in leukemia, gynecological cancer, and gastrointestinal cancer associated with ECOG studies. Other active clinical research programs include an experimental therapeutics program that recruits approximately 100 patients per year on phase I studies, and participation in a phase II CTEP consortium, providing an environment that fosters drug development that may be taken to ECOG; examples of this include several ECOG studies that include BMS-247550 (E2103, E3800, E2301), which underwent phase I-II development at AECC. The AECC serves an ethnically and economically diverse population of 1.3 million people, with 70 percent of residents being minority and 31 percent living below the poverty level, as reflected by nearly 70 percent minority recruitment on ECOG/CTSU trials. The establishment of a clinical research program in an affiliated municipal hospital and a community oncology program will serve to further enhance minority accrual. The recruitment of an internationally recognized physician-scientist (R. Perez-Soler) as Chairman of Department of Medical Oncology and Associate Cancer Center Director in July 2001 has been accompanied by recruitment of 17 new faculty members that will serve to further strengthen the active core of investigators and enhance the group's contributions to ECOG.